PortfoliosLab logoPortfoliosLab logo
KPTI vs. ARCT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KPTI vs. ARCT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and Arcturus Therapeutics Holdings Inc. (ARCT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KPTI achieves a 22.28% return, which is significantly lower than ARCT's 23.98% return.


KPTI

1D
-2.49%
1M
-3.23%
YTD
22.28%
6M
64.84%
1Y
111.76%
3Y*
-35.73%
5Y*
-41.77%
10Y*
-23.93%

ARCT

1D
-0.65%
1M
-11.32%
YTD
23.98%
6M
15.33%
1Y
-41.54%
3Y*
-34.37%
5Y*
-24.38%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

KPTI vs. ARCT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
KPTI
Karyopharm Therapeutics Inc.
22.28%-27.45%-21.82%-74.56%-47.12%-58.46%-30.05%
ARCT
Arcturus Therapeutics Holdings Inc.
23.98%-63.88%-46.18%85.91%-54.17%-14.68%155.18%

Correlation

The correlation between KPTI and ARCT is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (5Y)
Calculated over the trailing 5-year period

0.35

Correlation (All Time)
Calculated using the full available price history since Apr 17, 2020

0.34

The correlation between KPTI and ARCT shifts across timeframes, from 0.23 (1 year) to 0.35 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

KPTI:

$222.44M

ARCT:

$216.00M

EPS

KPTI:

-$13.00

ARCT:

-$1.81

PS Ratio

KPTI:

0.89

ARCT:

4.47

Total Revenue (TTM)

KPTI:

$151.12M

ARCT:

$46.80M

Gross Profit (TTM)

KPTI:

$145.13M

ARCT:

$40.72M

EBITDA (TTM)

KPTI:

-$93.05M

ARCT:

-$84.61M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KPTI vs. ARCT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI
KPTI Risk / Return Rank: 7676
Overall Rank
KPTI Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
KPTI Sortino Ratio Rank: 7878
Sortino Ratio Rank
KPTI Omega Ratio Rank: 7373
Omega Ratio Rank
KPTI Calmar Ratio Rank: 7777
Calmar Ratio Rank
KPTI Martin Ratio Rank: 7878
Martin Ratio Rank

ARCT
ARCT Risk / Return Rank: 2525
Overall Rank
ARCT Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
ARCT Sortino Ratio Rank: 2828
Sortino Ratio Rank
ARCT Omega Ratio Rank: 2828
Omega Ratio Rank
ARCT Calmar Ratio Rank: 2121
Calmar Ratio Rank
ARCT Martin Ratio Rank: 2626
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. ARCT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Arcturus Therapeutics Holdings Inc. (ARCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KPTIARCTDifference

Sharpe ratio

Return per unit of total volatility

1.20

-0.45

+1.65

Sortino ratio

Return per unit of downside risk

2.18

-0.08

+2.27

Omega ratio

Gain probability vs. loss probability

1.25

0.99

+0.26

Calmar ratio

Return relative to maximum drawdown

2.32

-0.56

+2.88

Martin ratio

Return relative to average drawdown

5.76

-0.79

+6.54

KPTI vs. ARCT - Sharpe Ratio Comparison

The current KPTI Sharpe Ratio is 1.20, which is higher than the ARCT Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of KPTI and ARCT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KPTIARCTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.20

-0.45

+1.65

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.44

-0.27

-0.17

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.26

-0.12

-0.14

Drawdowns

KPTI vs. ARCT - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, roughly equal to the maximum ARCT drawdown of -95.23%. Use the drawdown chart below to compare losses from any high point for KPTI and ARCT.


Loading charts...

Drawdown Indicators


KPTIARCTDifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

-95.23%

-4.27%

Max Drawdown (1Y)

Largest decline over 1 year

-48.36%

-74.53%

+26.17%

Max Drawdown (3Y)

Largest decline over 3 years

-90.08%

-86.71%

-3.37%

Max Drawdown (5Y)

Largest decline over 5 years

-98.36%

-89.87%

-8.49%

Max Drawdown (10Y)

Largest decline over 10 years

-99.15%

Current Drawdown

Current decline from peak

-98.73%

-93.85%

-4.88%

Average Drawdown

Average peak-to-trough decline

-75.26%

-72.98%

-2.28%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.49%

52.77%

-33.28%

Volatility

KPTI vs. ARCT - Volatility Comparison

Karyopharm Therapeutics Inc. (KPTI) has a higher volatility of 24.41% compared to Arcturus Therapeutics Holdings Inc. (ARCT) at 18.67%. This indicates that KPTI's price experiences larger fluctuations and is considered to be riskier than ARCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KPTIARCTDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.41%

18.67%

+5.74%

Volatility (6M)

Calculated over the trailing 6-month period

62.85%

40.13%

+22.72%

Volatility (1Y)

Calculated over the trailing 1-year period

94.09%

92.40%

+1.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.91%

91.77%

+3.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.48%

102.22%

-15.74%

Dividends

KPTI vs. ARCT - Dividend Comparison

Neither KPTI nor ARCT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

KPTI vs. ARCT - Financials Comparison

This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and Arcturus Therapeutics Holdings Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M20222023202420252026
35.07M
2.06M
(KPTI) Total Revenue
(ARCT) Total Revenue
Values in USD except per share items

Frequently Asked Questions


KPTI and ARCT have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KPTI has higher volatility (24.41%) compared to ARCT (18.67%). In terms of maximum drawdown, KPTI dropped -99.50% vs ARCT's -95.23%.

KPTI currently has the higher Sharpe Ratio (1.20 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KPTI and ARCT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer